23964-29-6

Usage

Uses

Used in Pesticide and Herbicide Applications:
3,5-Dichloro-4-hydroxybenzohydrazide is used as an active ingredient in pesticides and herbicides for its ability to control a wide range of pests and weeds. It targets and inhibits essential enzymes in the growth and reproduction of these organisms, thereby reducing their populations and protecting crops.
Used in Pharmaceutical and Agrochemical Synthesis:
In the pharmaceutical and agrochemical industries, 3,5-dichloro-4-hydroxybenzohydrazide is used as a precursor in the synthesis of various compounds. Its unique chemical structure allows it to be a key component in the development of new drugs and agrochemicals with improved efficacy and safety profiles.
Used in Environmental and Health Monitoring:
Due to its potential environmental and health impacts, 3,5-dichloro-4-hydroxybenzohydrazide is also used in monitoring programs to ensure that its use and disposal are carefully regulated. This helps to minimize any adverse effects on ecosystems and human health, promoting sustainable agricultural practices.

InChI:InChI=1/C7H6Cl2N2O2/c8-4-1-3(7(13)11-10)2-5(9)6(4)12/h1-2,12H,10H2,(H,11,13)

Upstream product

• 3337-59-5 methyl 3,5-dichloro-4-hydroxybenzoate 
• 17302-82-8 ethyl 3,5-dichloro-4-hydroxybenzoate 

Downstream Products

• 1251921-56-8 ethyl 2-(2-(3,5-dichloro-4-hydroxybenzoyl)hydrazinyl)-2-oxoacetate 
• 1191397-31-5 (Z)-ethyl 2-amino-2-(2-(3,5-dichloro-4-hydroxybenzoyl)hydrazono)acetate 

Relevant academic research and scientific papers

Compounds, Compositions and Methods Comprising 4N-Substituted Triazole Derivatives

The present invention relates to compounds, compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or 2 or encompassed by formula I) or compositions comprising these compounds, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives

The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

Compounds, Compositions and Methods Comprising Triazole Derivatives

The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-II) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

SALICYLIC ACID HYDRAZONES AS INHIBITORS OF THE ERK MAPKINASE PATHWAY AND FOR THE TREATMENT OF CANCER

The present invention includes methods of using certain salicylic acid hydrazones as inhibitors of cancer cell proliferation and/or survival and/or clonogenic cancer cell proliferation and/or survival. In particular, the compounds of the invention are use

Identification of alkylidene hydrazides as glucagon receptor antagonists

High throughput screening of our small molecule combinatorial library identified a class of benzoylnaphthalenehydrazones with modest affinity for the human glucagon receptor. Optimization of this initial hit through a series of targeted libraries and traditional medicinal chemistry led to ligands with nanomolar affinities. Pharmacological evaluation demonstrated that these ligands were competitive glucagon receptor antagonists. Intravenous administration of a representative benzoylnaphthalenehydrazone into rats attenuated glucagon-stimulated glucose levels.

1,3,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents

Compounds of the formula STR1 wherein: Y is an alkylene bridge of 3-9 carbon atoms; R' is lower-alkyl or hydroxy-lower-alkyl or 1-5 carbon atoms; R1 and R2 are hydrogen, halogen, lower-alkyl, lower-alkoxy, nitro, lower-alkoxycarbonyl

Heterocyclic substituted-phenoxyalkylisoxazoles as antiviral useful agents

Compounds of the formula STR1 wherein: Y is an alkylene bridge of 3-9 carbon atoms; Z is N or HC; R is hydrogen or lower-alkyl of 1-5 carbon atoms, with the proviso that when Z is N, R is lower-alkyl; R1 and R2 are hydrogen, halogen, lower-alkyl, lower-alkoxy, nitro, lower-alkoxycarbonyl or trifluoromethyl; and Het is selected from specified heterocyclic groups, are useful and antiviral agents, particularly against picornaviruses, including numerous strains of rhinovirus.